PIPERACILLIN AND TAZOBACTAM

Post-LOE

piperacillin and tazobactam

Novartis

ANDAINJECTIONINJECTABLE

Approved

Aug 2014

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PIPERACILLIN AND TAZOBACTAM (piperacillin and tazobactam) by Novartis is 12. Approved for older) for the treatment of appendicitis (complicated by rupture, abscess), peritonitis caused by beta-lactamase producing isolates of escherichia coli and 12 more indications. First approved in 2014.

Drug data last refreshed 18h ago

Mechanism of Action

12.1 Mechanism of Action Piperacillin and tazobactam for injection is an antibacterial drug [ see ] . 12.2 Pharmacodynamics The pharmacodynamic parameter for piperacillin/tazobactam that is most predictive of clinical and microbiological efficacy is time above MIC. 12.3 Pharmacokinetics The mean…

Worked on PIPERACILLIN AND TAZOBACTAM at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

PIPERACILLIN AND TAZOBACTAM

Mechanism of Action

Indications (15)